glp 1 agonists and inflammation The anti-inflammatory feature of glucagon-like peptide-1 its based diabetes drugs—Therapeutic potential exploration in lung injury A Closer Look at the

J.BorlaugB

References Willerson JT, Ridker PM (2004) Inflammation as a cardiovascular risk factor

In January of 2024 we put in the requirement that you have type 2 diabetes for certain GLP-1s, and then we put in a BMI of 35 or higher for the weight loss GLP-1s

2024;187(14):360218 e20

doi:10.1038/s41366-025-01859-6 51

Retatrutide metabolic benefits Retatrutide produces all of the metabolic benefits seen with Mounjaro plus additional improvements that appear unique to triple agonism: Blood sugar control: HbA1c reductions of 1.3% to 2.0% at doses of 4-12 mg in type 2 diabetes Blood pressure: Systolic blood pressure reduction of up to 14.0 mmHg at the highest dose (roughly double what Mounjaro achieves) Lipids: Non-HDL cholesterol and triglyceride reductions Prediabetes reversal: 72% of participants with prediabetes at baseline reverted to normoglycemia Inflammatory markers: Significant reductions in high-sensitivity C-reactive protein But the standout metabolic benefit, the one that has researchers most excited, is the effect on liver health